Leerink Partners Reiterates Buy Rating on ARS Pharmaceuticals
Leerink Partners keeps a buy rating on ARS Pharmaceuticals with a $24 price target, a 181.03% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating on ARS Pharmaceuticals, Inc. (SPRY) on June 25, 2026, with a price target of $24.
- Leerink Partners's $24 price target implies 181.03% upside from ARS Pharmaceuticals, Inc.'s ($SPRY) current $8.54 share price.
- Shares of ARS Pharmaceuticals traded near $10.54 on Thursday, with a market cap of about $991 million.
- Several insiders, including the Chief Commercial Officer, engaged in planned sales and purchases of ARS stock in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 25, 2026, Leerink Partners reiterated its buy rating on ARS Pharmaceuticals, Inc. (NasdaqGM: SPRY), maintaining a price target of $24. The analyst Roanna Ruiz believes the stock has significant upside potential.
Leerink Partners vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ARS Pharmaceuticals, Inc. Stock Up 45.0%
Shares of ARS Pharmaceuticals traded near $10.54 on Thursday. The company, with a market cap of approximately $991 million, operates in the biotechnology sector. It has a beta of 0.826, indicating less volatility compared to the broader market. Over the past year, the stock has ranged from a low of $6.66 to a high of $18.90. The 50-day moving average stands at $8.56, while the 200-day moving average is $9.38. The firm has a strong liquidity position with a current ratio of 4.943 and a quick ratio of 4.645, although its debt-to-equity ratio is high at 279.238.
$SPRY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
ARS Pharmaceuticals reported revenue of $98.99 million, with a slight growth of 1.845%. However, the company posted a net margin of -200.004% and a return on equity of -136.403%, reflecting ongoing financial challenges. The next earnings release is anticipated on August 13, 2026.
Insider Buying and Selling at ARS Pharmaceuticals, Inc.
In recent insider activity, Eric Karas, the Chief Commercial Officer, executed both planned and unplanned transactions. On June 12, 2026, Karas sold 25,000 shares at $10.00 each under a Rule 10b5-1 plan. On the same day, he also purchased 25,000 shares at $1.50, not as part of a planned transaction. Additionally, Alexander Fitzpatrick, the Chief Legal Officer, sold 3,355 shares at $10.00 per share in a planned sale.
Analysts Set New Price Targets
On June 25, 2026, Leerink Partners maintained its buy rating with a $24 price target. Earlier, Cantor Fitzgerald also reiterated a buy rating with a $30 target on May 28, 2026. The consensus among analysts is bullish, with a mean price target of $28.80 based on five opinions.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., headquartered in San Diego, California, is a biopharmaceutical company focused on developing treatments for severe allergic reactions. Its flagship product, Neffy, is a needle-free intranasal delivery of epinephrine for emergency treatment of allergic reactions like anaphylaxis. Founded in 2015, the company is led by CEO Richard E. Lowenthal and employs 154 people.
Bottom Line
Leerink Partners' reiteration of a buy rating on ARS Pharmaceuticals reflects confidence in the company's potential, particularly with its innovative treatment for allergic reactions. Investors will be watching upcoming earnings for further insights into the company's financial progress. As always, it's important to remember that analyst ratings are based on current data and assumptions, and actual performance may vary.
Get ARS Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SPRY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.